PointCheck for Low White Blood Cell Count
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests PointCheck, a new non-invasive device designed to help cancer patients manage low white blood cell counts caused by chemotherapy. The trial aims to assess the device's ease of use at home and its effectiveness. It seeks cancer patients, particularly those with conditions like lymphoma or breast cancer, who are undergoing chemotherapy with a high risk of reducing white blood cells. Participants will try PointCheck twice in one session and simulate home use. As an unphased trial, this study allows patients to contribute to innovative research that could enhance at-home care for cancer patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on testing a device, so you may not need to change your medication routine, but it's best to confirm with the study team.
What prior data suggests that PointCheck is safe for monitoring chemotherapy-induced neutropenia?
Research has shown that PointCheck is a non-invasive tool designed to detect low white blood cell counts, particularly those resulting from chemotherapy. This study primarily examines the ease of use of PointCheck. Safety data from similar non-invasive devices indicate they are generally well-tolerated, meaning users typically do not experience negative side effects.
Since PointCheck is a monitoring tool and not a drug, it does not introduce substances into the body, making adverse reactions unlikely. Most safety concerns would focus on the device's accuracy in measuring white blood cell counts. However, because this study does not involve administering a new medication, safety risks remain minimal.
Overall, as a non-invasive tool, PointCheck is expected to be safe for users. The study's main focus is on its ease of use and accuracy in measuring white blood cell levels.12345Why are researchers excited about this trial?
PointCheck is unique because it's a non-invasive technique aimed at detecting low white blood cell counts using a simple finger scan. Unlike traditional methods that require blood samples and lab work, PointCheck offers rapid, on-the-spot results without the need for needles. Researchers are excited about this trial because it could lead to quicker diagnosis and monitoring, which is especially beneficial for patients who need frequent checks, like those undergoing chemotherapy. This could significantly improve patient comfort and streamline the process of managing conditions that affect white blood cell levels.
What evidence suggests that PointCheck is effective for monitoring low white blood cell count?
Research has shown that PointCheck, the investigational tool studied in this trial, holds promise for detecting low levels of certain white blood cells, known as neutropenia, in patients receiving chemotherapy. Studies have demonstrated that even first-time users can effectively use PointCheck at home, indicating the device's ease of use and reliability for checking white blood cell levels without drawing blood. Early results also suggest that PointCheck accurately identifies severe cases of neutropenia. These findings are encouraging for patients who require regular monitoring without frequent hospital visits.678910
Who Is on the Research Team?
Mark Sloan, MD
Principal Investigator
Boston Medical Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with hematological cancers or breast cancer, who are undergoing high/intermediate risk neutropenia-inducing chemotherapy. They must understand the study and consent to participate. Excluded are those with uncontrolled low blood pressure, significant hand tremors or abnormalities, circulating tumor cells in labs, leukemia, certain rheumatologic conditions affecting circulation, or any condition that may risk their safety or affect results.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are tested twice with PointCheck during the same session and usability in an at-home simulated environment is evaluated
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PointCheck
Find a Clinic Near You
Who Is Running the Clinical Trial?
Leuko Labs, Inc.
Lead Sponsor
National Cancer Institute (NCI)
Collaborator